Characterization of HIV humoral immunity during analytical treatment interruption
Although antibody levels did not predict viral rebound, tracking their longitudinal changes provided meaningful information about viral replication patterns and immune reactivation during and after rebound, offering a practical tool for monitoring ATI outcomes.
Authors
- Clara Di Germanio (ORCID: https://orcid.org/0000-0002-6047-211X)
- Brendan G. Balasko
- George Noutsios
- Rajesh T. Gandhi
- Patricia G. Villaflor
- Jonathan Z. Li
- Davey M. Smith
- Philip J. Norris
- Michael P. Busch
- Steven Deeks
- Ronald J. Bosch
Institutions
- Brigham and Women's Hospital (US)
- Bio-Rad (United States) (US)
- Harvard University (US)
- University of California, San Francisco (US)
- UC San Diego Health System (US)
- Pacific Research Institute (US)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Vitalant (US)
- University of San Francisco (US)
Publication Details
- Journal
- Journal of Clinical Virology
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1016/j.jcv.2026.105930
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00